Showing results (211-220 of 458) with videos related to

Sort By:
Pageof 46
Pediatric Blood & Cancer|June 2, 2025
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupHetal Dholaria, Arlene Naranjo, Fan F Zhang, et al.
JCO Precision Oncology|July 12, 2021
Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG UptakeAndrew Samoyedny, Abhay Srinivasan, Lisa States, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing programChristopher L Morton, Peter J Houghton, Richard Gorlick, et al.
Cancer Research|August 1, 1996
Familial predisposition to neuroblastoma does not map to chromosome band 1p36J M Maris, S M Kyemba, T R Rebbeck, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|June 18, 2011
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastomaDaniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Pageof 46